Below you will find the program for both conference days, outlining the scheduled sessions and activities. For each session, timing, speakers and content are provided. Pending speakers will be added over time.
08:45 – Opening by Prof. dr. Marlies Reinders
Dean of the Faculty of Medicine at LUMC, the Netherlands
Moderators – Joanne Verweij & Jeremia Pyuza
The anti-D divide
09:00 – Why are we here today?
Ellen van der Schoot (Sanquin, University of Amsterdam, the Netherlands)
09:10 – an HDFN patient journey in Africa and Netherlands
Rose Murage (Allohope Foundation, Kenya) & NL patient
09:30 – AFRICARhE: a Landscape Analysis & systematic review
Rafiki Mjema (KCMC, Tanzania) & Assefa Desalew (Haramaya University, Ethiopia)
09:50 – A systematic review on RhD immunization from India
Shamee Shastry (KMC Manipal,India)
10:10 – RhD prophylaxis & immunization in Latin America
Jesus Andrés Benavides Serralde (Universidad ICESI, Colombia)
10:30 – Coffee
Polyclonal anti-D initiatives: past, present, future
> Experiences from Australia, South Africa and the Netherlands
11:00 – The Netherlands: in the past non-profit self-sufficient, female donors
Ed Slot (Sanquin, the Netherlands)
11:10 – Rh program in Australia
Kobie von Wielligh (Australian Red Cross, Australia)
The future: blueprint for European plasma collection
11:20 – Steps to come to self sufficiency in Europe
Pierre Tiberghien (European Blood Alliance, France)
11:30 – Women – for – women: anti-D plasma donor recruitment
Eva Maria Merz (Sanquin Research, VU, the Netherlands)
11:40 – Role of European Medicines Agency and regulatory frameworks
Sandra Dang (European Medicines Agency, the Netherlands)
The future in Africa
11:50 – Anti-D plasma collection in Ethiopia
Ashenafi Amare (Ethiopian Blood and Tissue Service, Ethiopia)
12:00 – Plasma fractionation in South Africa
Maishibe Nthlane (NBI, South-Africa)
12:10 – Discussion
12:30 – Lunch
Moderators – Steve Spitalnik (United States) & Priscus Mapendo (Tanzania)
Steps towards monoclonal development
13:30 – 3rd interim analysis of a real-world study in Rh negative pregnant women in India (RhYTHM study)
Pratik Shah (Bharat Pharma, India)
13:45 – Sanquin monoclonal pipeline
Gestur Vidarsson ( Sanquin Research, UMCU, the Netherlands)
14:00 – Australian initiatives
Ian Wicks (The Walter and Eliza Hall Institute of Medical Research, Australia)
14:15 – LFB experience
Philippe Mondon (LFB, France)
14:30 – Ethical challenges in monoclonal trials
Heidi Matisonn (University of Cape Town, South Africa)
14:45 – Panel discussion
Parallel workshops: working towards a position statement
15:00 – Parallel workshops including:
Advocacy & Policy Pathways
Research Ethics
Plasma Collection – Increasing Production
Plasma Collection – Donor Recruitment
Patient & Public Involvement
Healthcare Provider’s Perspectives Anti-D Dosage
16:45 – Plenary: summary of the afternoon and concrete action plans
17:00 – Closure
18:30 Drinks and dinner
09.00 – Introduction & welcome
Joanne Verweij & Masja de Haas & Enrico Lopriore
Session 1: screening strategies
Moderator: Masja de Haas & Claudia Folman
09:10 — The 7th John Gorman Lecture
State of the Art from an international perspective: which women do we test for which red blood cell antibodies
Yanli Yi (Guangzhou Blood Center, China)
Introduced by Steven Spitalnik (Columbia University, United States)
09.30 — Variations in timing, frequency and methods – results from the Dionysus & questionnaire
Renske van ‘t Oever (LUMC and Sanquin, the Netherlands)
09:40 — 1 or 2 times screening, for all women or for subgroups only?
One time screening
Nuria Nogues Galvez (Immunohematology Laboratory Barcelona, Spain)
Two times screening
Edwin Massey, (Welsh Blood Service, UK)
Second screening for subgroup of D-positives: the c-negatives
Claudia Folman (Sanquin, the Netherlands)
Discussion panel on set of statements with all speakers of session 1
10:15 — Fetal genotyping on cell free fetal DNA: replacing paternal typing?
Discussion is introduced by two short presentations on the rationale for their own program:
The European perspective
Frederik Clausen (Copenhagen University Hospital, Denmark)
The US perspective
Ken Moise (Dell Medical School, United States)
Discussion panel on set of statements with all speakers of session 1
10:45— Coffee
Session 2: diagnostics and referral
Moderator: Masja de Haas & Joanne Verweij
11:10 — State of the Art from an international perspective: how to timely identify in the lab women at high risk and possibly needing intervention
Cecile Toly Ndour (National Reference Center Perinatal Hemobiology, France)
11:25 — Variations high risk identification, cut-offs/thresholds – results from the Dionysus & questionnaire
Marloes Kuijpers (Sanquin, LUMC, the Netherlands)
11:35 — Consensus Recommendations on antibody testing from a Modified Delphi Process in Canada
Gwen Clarke (University of Alberta, Canada)
11:50 — Is there added value of biological assays?
Claudia Folman (Sanquin, the Netherlands)
Discussion panel on set of statements with all speakers of session 1 & 2 on high risk identification
12:30 — Lunch
Session 3: antenatal management
Moderator: Joanne Verweij
13:30 — State of the Art from an international perspective: antenatal treatment – past, present and future
Ken Moise (Dell Medical School, United States)
13:50 — Variations in antenatal management – results from the Dionysus & questionnaire
Marloes Kuijpers (LUMC, the Netherlands)
Discussion panel
14:00 — Delay of IUT with IVIG and/or plasmapheresis
Two short presentations on the rationale for their own management strategy:
Pro
> John Smoleniec (South Western Sydney LHN, Australia)
Contra
> Roland Devlieger (UZ Leuven, Belgium)
Discussion panel
14:30 — The IUT approach
Three short presentations on the rationale for their own management strategy:
Placental insertion only
Jean-Marie Jouannic ( Sorbonne University Paris, France)
Intra-hepatic only
Daniela Casati (Buzzi Children’s Hospital Milan, Italy)
50/50 placental insertion/intra-hepatic
Femke Slaghekke (LUMC, the Netherlands)
15:00 — Tea
Session 4: postnatal management
Moderator: Enrico Lopriore, Jillian Baker
15:20 — State of the Art from an international perspective: postnatal management
Jana Lozar Krivec (Ljubljana University, Slovenia)
15:30 — Variations in postnatal management – results from the Dionysus & questionnaire
Derek de Winter (LUMC, Netherlands)
Discussion panel
15:40 — Delay the induction of labor >38 weeks
Two short presentations on the rationale for their own management strategy:
Pro
> Enrico Lopriore (LUMC, the Netherlands)
Contra
> Roland Devlieger (UZ Leuven, Belgium)
Discussion panel
16:10 — IVIG to prevent exchange transfusion
Two short presentations on the rationale for their own management strategy:
Pro
> Tim Bahr (University of Utah, United States)
Contra
> Maria Pessoa Dos Santos (Fundação Oswaldo Cruz (FIOCRUZ), Brazil)
> Plenary workshop & closing session
16:40 — Barriers, facilitators and best practices across countries
17:00 — Closing Session
Towards a coordinated global research and policy agenda for HDFN